Clearmind Medicine Inc. (NASDAQ: CMND) filed an international patent application under the Patent Cooperation Treaty on March 10, 2026 for a novel combination therapy that pairs its proprietary 5‑methoxy‑2‑aminoindane (MEAI) with palmitoylethanolamide (PEA). The filing targets weight loss and metabolic dysfunction‑associated steatotic liver disease (MASLD), conditions that affect more than 890 million adults worldwide and 30 % of the global adult population, respectively.
The patent, developed in collaboration with NeuroThera Labs Inc., a subsidiary of SciSparc Ltd., protects the use of the MEAI‑PEA combination for these indications. By securing intellectual property in a high‑growth market, Clearmind positions itself to offer a safe, non‑hallucinogenic neuroplastogen that could compete with GLP‑1 agonists for obesity and MASLD treatment. The company’s CEO, Dr. Adi Zuloff‑Shani, said, "The publication of this international patent is part of our mission to develop innovative, proprietary and transformative therapies for underserved metabolic and neurological conditions."
Clearmind’s IP portfolio now includes 31 granted patents and 19 patent families, and the new filing expands its therapeutic focus beyond alcohol use disorder and binge‑behavior indications. The weight‑loss drug market is projected to reach $226 billion by 2035, and the company’s MEAI platform could capture a share of this expanding opportunity. The collaboration with NeuroThera Labs leverages PEA’s anti‑inflammatory properties, potentially enhancing efficacy and safety in the obesity and liver health space. "By combining our MEAI platform with PEA from our partners at NeuroThera Labs, we are positioning ourselves to address the escalating demand for effective, tolerable and safe treatments in the obesity and liver health space," Dr. Zuloff‑Shani added.
The filing signals Clearmind’s intent to broaden its pipeline and strengthen its competitive moat. While the patent is a publication of an application and not a granted patent, it establishes early protection and sets the stage for future clinical development and regulatory submissions. The move underscores the company’s strategy to leverage its MEAI platform across multiple indications, potentially creating new revenue streams as the company continues to pursue transformative therapies in the psychedelic‑derived therapeutics space.
The announcement does not include immediate market reaction data, but the filing is expected to influence investor perception of Clearmind’s long‑term growth prospects and its ability to enter the lucrative weight‑loss and MASLD markets. The company’s focus on a non‑hallucinogenic, neuroplasticity‑based approach may differentiate it from existing GLP‑1 agonists and other metabolic therapies, positioning Clearmind for future clinical and commercial success.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.